Regulatory Approval
NATCO Pharma and Lupin Receive US FDA Approval for Eribulin Mesylate Injection
NSE
NATCOPHARM
BSE
524816
NATCO Pharma Limited, in partnership with Lupin Limited, has received approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. The approved product is a generic equivalent of Halaven® Injection and addresses treatment needs in metastatic breast cancer and liposarcoma.
PRICE-SENSITIVE TRIGGER
Event: US FDA approval received for Eribulin Mesylate Injection ANDA.
Type: Regulatory Approval
Impact: Positive
Immediate Effect: The approval enables NATCO and its alliance partner Lupin to commercialize the generic version of Eribulin Mesylate Injection in the U.S. market, expanding their oncology product portfolio and creating a new revenue opportunity.
Key Metrics:
- Reference Product: Halaven® (Eribulin Mesylate Injection)
- Dosage Strength: 1 mg/2 mL (0.5 mg/mL)
- Market: United States
- Reference Product Annual Sales: USD 43.7 million
- Sales Period: IQVIA MAT April 2026
Highlight:
- Market Opportunity: Reference drug Halaven® recorded annual U.S. sales of approximately USD 43.7 million as of April 2026.
What Happened ?
NATCO Pharma Limited and its alliance partner Lupin Limited announced that the United States Food and Drug Administration has approved NATCO’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
The approved product is bioequivalent and therapeutically equivalent to Eisai’s reference listed drug (RLD), Halaven® Injection. The approval allows the companies to market the product in the U.S. pharmaceutical market.
Eribulin Mesylate Injection is an oncology product indicated for the treatment of adult patients with metastatic breast cancer and certain patients with unresectable or metastatic liposarcoma who have previously received anthracycline-containing treatment regimens.
Key Details
Product Approval and Commercial Significance:
- US FDA approved NATCO’s ANDA for Eribulin Mesylate Injection.
- Approval was received in collaboration with alliance partner Lupin Limited.
- The product is a generic equivalent of Halaven® Injection marketed by Eisai.
- The drug is indicated for metastatic breast cancer treatment after prior chemotherapy regimens.
- The product is also indicated for unresectable or metastatic liposarcoma following anthracycline-based treatment.
- Approval strengthens NATCO’s oncology-focused generic portfolio in regulated markets.
- The launch enhances the company’s presence in specialty injectable oncology products.
- The approval provides access to an established U.S. oncology market opportunity.
Note:
- NATCO continues to expand its regulated-market oncology portfolio through complex generic and specialty pharmaceutical products, with the U.S. remaining a key growth market.
Risk Analysis
Summary:
- While regulatory approval has been secured, commercial success will depend on launch execution, competitive intensity in the generic market, pricing dynamics, and market penetration.
Key Risks:
- Generic competition may impact pricing and profitability.
- Market share acquisition depends on commercial execution and customer adoption.
- Future regulatory compliance requirements remain ongoing.
- Oncology product demand can be influenced by treatment alternatives and market dynamics.
- Supply chain and manufacturing performance remain critical for successful commercialization.
Worst Case Scenario:
- Higher-than-expected competition or pricing pressure could limit revenue realization despite regulatory approval.
Risk Level: Medium
Company Commentary
- NATCO and Lupin announced receipt of US FDA approval for Eribulin Mesylate Injection.
- The approved product is bioequivalent to the reference listed drug Halaven® Injection.
- The therapy addresses metastatic breast cancer and metastatic or unresectable liposarcoma indications.
- The reference product generated annual U.S. sales of approximately USD 43.7 million based on IQVIA MAT April 2026 data.
- NATCO highlighted its continued focus on specialty pharmaceuticals, oncology products, APIs, and regulated global markets.
Official Exchange Filing: NATCO Pharma Limited